12月23日，嘉事堂盘中下跌2.06%，截至14:03，报15.23元/股，成交1.20亿元，换手率2.69%，总市值 44.43亿元。 资料显示，嘉事堂药业股份有限公司位于北京市海淀区昆明湖南路11号1号楼，成立日期1997年4月22 日，上市日期2010年8月18日，公司主营业务涉及以医药批发、零售为主营业务模式的医药商业经营。 主营业务收入构成为：商业收入100.00%。 资金流向方面，主力资金净流出466.50万元，特大单买入591.50万元，占比4.91%，卖出0.00元，占比 0.00%；大单买入1294.03万元，占比10.74%，卖出2352.03万元，占比19.53%。 嘉事堂所属申万行业为：医药生物-医药商业-医药流通。所属概念板块包括：冷链物流、小盘、证金汇 金、医疗器械、医药电商等。 嘉事堂今年以来股价涨19.45%，近5个交易日跌1.36%，近20日跌0.65%，近60日涨11.33%。 截至11月20日，嘉事堂股东户数2.20万，较上期减少3.28%；人均流通股13248股，较上期增加3.39%。 2025年1月-9月，嘉事堂实现营业收入144.59亿元，同比减少21.80%；归母 ...

证券日报网讯12月10日，嘉事堂（002462）在互动平台回答投资者提问时表示，公司始终坚持做好主营 业务，提升经营质量，努力为投资者创造良好回报。 ...

格隆汇12月10日丨嘉事堂(002462.SZ)在投资者互动平台表示，公司目前有胸腺肽、免疫球蛋白等相关 药品的销售业务。 ...

证券日报网讯嘉事堂（002462）11月26日在互动平台回答投资者提问时表示，公司目前有奥司他韦、速 福达等药品的销售业务。 ...

每经AI快讯，有投资者在投资者互动平台提问：请问公司是否有保健白酒业务，如国公酒、鹿茸酒、 人参酒等白酒？ （文章来源：每日经济新闻） 嘉事堂（002462.SZ）11月26日在投资者互动平台表示，公司目前没有您提到的业务。 ...

Core Viewpoint - The stock of Jia Shitang has shown a mixed performance in recent trading sessions, with a year-to-date increase of 19.45% but a slight decline in the last five days, indicating potential volatility in investor sentiment [1][2]. Group 1: Stock Performance - On November 20, Jia Shitang's stock rose by 2.01%, reaching 15.23 CNY per share, with a trading volume of 63.68 million CNY and a turnover rate of 1.46%, resulting in a total market capitalization of 4.443 billion CNY [1]. - Year-to-date, Jia Shitang's stock has increased by 19.45%, with a 1.10% decline over the last five trading days, a 7.78% increase over the last 20 days, and a 4.75% increase over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on May 8, where it recorded a net buy of -534.52 million CNY [1]. Group 2: Financial Performance - For the period from January to September 2025, Jia Shitang reported operating revenue of 14.459 billion CNY, a year-on-year decrease of 21.80%, and a net profit attributable to shareholders of 141 million CNY, down 38.81% year-on-year [2]. - Since its A-share listing, Jia Shitang has distributed a total of 874 million CNY in dividends, with 216 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, Jia Shitang had 22,700 shareholders, an increase of 3.39% from the previous period, with an average of 12,814 circulating shares per shareholder, a decrease of 3.28% [2]. Group 4: Industry Classification - Jia Shitang is classified under the Shenwan industry as part of the pharmaceutical and biological sector, specifically in pharmaceutical commerce and distribution, with involvement in various concept sectors including small-cap stocks, pharmaceutical e-commerce, cold chain logistics, and medical devices [2].

Core Viewpoint - The company, Jia Shi Tang (002462.SZ), has stated that it currently has no cooperation with He Fu China [1] Group 1 - The company confirmed its lack of collaboration with He Fu China on the investor interaction platform [1]

Core Viewpoint - The company, Jia Shitang (002462.SZ), has confirmed its involvement in the sales of flu-related pharmaceuticals [1] Group 1 - The company is currently engaged in the sales business of flu-related medications [1]

Core Viewpoint - The pharmaceutical commercial sector is experiencing a significant downturn, with multiple companies facing declines in stock prices [2] Company Performance - Yiyigou has seen a drop of over 7% in its stock price [2] - Other companies such as Shuyupingmin, Kaikai Industry, Jiashitang, and Yifeng Pharmacy are also experiencing declines [2]

Core Insights - The pharmaceutical commercial sector experienced a rise of 1.05% on November 14, with significant gains led by the stock of Jiyu Pingmin, which surged by 20.03% [1] - The Shanghai Composite Index closed at 3990.49, down 0.97%, while the Shenzhen Component Index closed at 13216.03, down 1.93% [1] Stock Performance - Jiyu Pingmin (301017) closed at 16.66 with a gain of 20.03%, trading volume of 141,800 shares and a transaction value of 227 million [1] - Renmin Tongtai (600829) and Kaikai Industry (600272) also saw notable increases of 10.04% and 10.03%, respectively [1] - The pharmaceutical sector's stocks showed a mixed performance, with some stocks like Jianfa Zhixin (301584) and Runda Medical (603108) declining by 3.33% and 1.59% respectively [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 497 million from institutional investors, while retail investors contributed a net inflow of 590 million [2][3] - The main stocks experiencing significant net inflows from retail investors included Jiyu Pingmin and Kaikai Industry, while institutional investors showed a preference for stocks like Kaikai Industry [3]